Novo Nordisk A/S (NVO) Stock Forecast & Price Target

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2025?

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $81.00, with a high forecast of $160.00 and a low forecast of $54.00.

Should I buy or sell Novo Nordisk A/S stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There is currently 1 sell rating, 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

Does Novo Nordisk A/S's stock price have much upside?

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 39.18% based on their 12-month stock forecasts.

Has Novo Nordisk A/S been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Novo Nordisk A/S's stock had 6 upgrades and 4 downgrades by analysts.

What analysts cover Novo Nordisk A/S?

Novo Nordisk A/S has been rated by research analysts at Barclays, Berenberg Bank, BNP Paribas, BNP Paribas Exane, Dbs Bank, Hsbc Global Res, HSBC, Rothschild & Co Redburn, Sanford C. Bernstein, TD Cowen, UBS Group, and Zacks Research in the past 90 days.

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Analysts like Novo Nordisk A/S less than other "medical" companies. The consensus rating for Novo Nordisk A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVO compares to other companies.